News

Collaboration can result in greater success than what one can achieve alone, and for women physicians, this rings truer than ever before, writes Jill M. Farmer, DO, MPH.

In light of National Women Physicians Day, the assistant clinical professor at Vanderbilt University School of Medicine commented on the roles women have played historically, and her perspective on where they stand now. [WATCH TIME: 12 minutes]

Theresa Sevilis, DO, writes on picking a career path in medicine as a woman, and how deciding to jump ship from a traditional path was among the best decisions she's made.

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.

Although findings suggest better efficacy of consyntropin when compared with vigabatrin, the randomized trial was underpowered due to incomplete enrollment.

Treatment with blarcamesine resulted in statistically significant improvements on the new primary end point and significantly reduced Rett syndrome symptoms through changes in potential biomarkers of disease pathology.

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society discussed the importance and flexibility of wellness approaches for patients with MS during the pandemic. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Episode 18 of the AUPN Leadership Minute features Donald S. Higgins, Jr., MD, of the VHA; and John Greenfield, MD, PhD, of University of Connecticut School of Medicine. [WATCH TIME: 7 minutes]

The senior director of patient management, care, and rehabilitation at the National Multiple Sclerosis Society provided insight on the variability in wellness recommendations to treat symptoms of multiple sclerosis. [WATCH TIME: 6 minutes]

The cognitive neurologist at the University of California, San Francisco provided insight on the research needed to explain more about COVID-19’s pathogenesis and the realistic possibility of developing neurocognitive disorders.

A greater proportion of patients treated with 0.25 mg/kg of tenecteplase were free from disability or achieved functional independence compared with those treated with 0.40 mg/kg doses, or alteplase.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on ongoing developments from the organization, particularly the diagnostics accelerator, which aims at identifying a better way to diagnose Alzheimer disease. [WATCH TIME: 6 minutes]

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

The cognitive neurologist at the University of California, San Francisco discussed a specific analysis that evaluated differences in cerebrospinal fluid in patients who develop cognitive changes following COVID-19 infection. [WATCH TIME: 6 minutes]

Regardless of baseline body mass index, patients who had increases or decreases of 5% or more in BMI had faster cognitive decline over a 5-year follow-up period.

After a prior phase 2 failure in CHANGE-MS showed signs of promise for progressive disease, the final patient visit has been completed in a trial of temelimab in relapsing disease, with results expected before the end of March 2022.

Overall, more than 40% of the cohort were eligible for a migraine preventive medication, but only 16.8% reported currently using one.

The association was found independent of vascular risk factors, suggesting a dose-response association between stroke severity and recurrence with risk of dementia.

Discussing recent technological advancements in the AD field, the founding executive director of the Alzheimer’s Drug Discovery Foundation noted the doors that these innovations have opened. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

The founding executive director of the Alzheimer’s Drug Discovery Foundation commented on the potential to detect patients at-risk for Alzheimer disease at an earlier age. [WATCH TIME: 4 minutes]

After discontinuing dosing in the phase 3 GENERATION HD1 study in 2021, Roche is designing a new phase 2 trial for tominersen, its investigational antisense oligomer for Huntington disease.

In addition to improving constipation in patients with Parkinson disease, ENT-01 also helped improve Mini-Mental State Examination scores, an exploratory measure of cognition.

The study is the first to support the validity of the ESS-CHAD in pediatric participants under the age of 12 years, showing internal consistency, test-retest reliability, responsiveness to change, and construct validity.

Neurology News Network for the week ending January 29, 2022.

An expert-led panel discuss the implications of recent findings that suggest a causative relationship between infection with Epstein-Barr virus and development of multiple sclerosis.